CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Gilead’s multiple bets on fast Car production
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
ASCO 2024 – new matching strategy delays Caribou
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
